The growing number of detected tyrosine kinase fusions in predominantly EGFRwt/KRASwt adenocarcinomas (including ALK, RET, and ROS1) are also becoming increasingly important in the therapeutic setting, as these alterations are/may become targets for specialized molecular agents. This evidence concerns the gene ROS1 and adenocarcinoma.